Érképzodést gátló kezelés emésztoszervi daganatokban

Translated title of the contribution: Antiangiogenic therapy for gastrointestinal tumors

Gábor Lakatos, Zsolt Tulassay

Research output: Contribution to journalReview article

Abstract

Angiogenesis plays a major role in the pathogenesis of many disorders. Vascular endothelial growth factor has been shown to be the key regulator of normal and pathological angiogenesis. Increased expression of VEGF has been associated with tumor neovascularization, metastasis and proliferation of cancer cells. Bevacizumab, a monoclonal antibody against VEGF, has shown promising preclinical and clinical activity against different types of cancer, particularly in combination with chemotherapy. There is an increasing evidence that bevacizumab has a disease-modifying effect in metastatic colorectal carcinoma (CRC), and also in advanced hepatocellular carcinoma. Further investigation is needed to evaluate the role of antiangiogenic therapeutic strategies in other gastrointestinal malignancies. This review summarizes recent knowledge about antiangiogenic therapy for gastrointestinal cancers.

Translated title of the contributionAntiangiogenic therapy for gastrointestinal tumors
Original languageHungarian
Pages (from-to)2317-2324
Number of pages8
JournalOrvosi hetilap
Volume149
Issue number49
DOIs
Publication statusPublished - Dec 7 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antiangiogenic therapy for gastrointestinal tumors'. Together they form a unique fingerprint.

  • Cite this